Proficio Capital Partners LLC Buys Shares of 21,212 Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 21,212 shares of the biotechnology company’s stock, valued at approximately $706,000.

A number of other hedge funds have also modified their holdings of EXEL. USA Financial Formulas purchased a new position in shares of Exelixis during the 4th quarter worth approximately $32,000. Principal Securities Inc. increased its stake in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares in the last quarter. Kestra Investment Management LLC purchased a new position in shares of Exelixis during the 4th quarter worth approximately $39,000. Brooklyn Investment Group purchased a new position in shares of Exelixis during the 3rd quarter worth approximately $42,000. Finally, UMB Bank n.a. increased its stake in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Exelixis

In related news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total transaction of $331,430.40. Following the transaction, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total transaction of $388,000.00. Following the transaction, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Stock Down 0.6 %

Shares of EXEL opened at $36.96 on Friday. The firm has a market cap of $10.34 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company’s fifty day moving average is $35.61 and its two-hundred day moving average is $32.86. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on EXEL shares. JMP Securities reissued a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. Stifel Nicolaus lifted their target price on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. BMO Capital Markets cut shares of Exelixis from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. Finally, Citigroup lifted their target price on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.